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Results: Of the 21 patients, 5 (24%) had mediastinal nodal involve-
ment in different areas on PET compared to CT. In three patients, there 
were less nodal stations involved on PET vs. CT (stations 10, 5, 7; 
4R and 4L, respectively); in two patients, PET identiﬁed CT-negative 
mediastinal stations (station 5 and 7, respectively). PET based planning 
thus resulted in an increased nodal GTV in 2 patients and a decrease in 
3 patients. Taken all patients together, however, there were no signiﬁ-
cant differences in GTV, lung, and esophageal parameters between CT 
and PET-based plans. For CT vs. PET: V20 25.6±2.4 vs. 25.6±12.3 % 
(p=1.00); MLD: 13.7±5.6 vs. 13.7±5.6 Gy (p=0.89); MED: 24.4±8.6 
vs. 24.1±8.5 Gy (p=0.50); Dmax: 45.8± 2.9 vs. 45.7±2.9 Gy (p=0.32). 
For the three patients in whom the nodal GTV decreased with PET, the 
V20 decreased from 25.5± 4.9 to 22.0±7.1 % (p=0.10); MLD: 13.2±2.5 
vs. 11.6±3.3 Gy (p=0.10); MED: 25.0±8.5 vs. 21.0plusmn;5.7 Gy 
(p=0.10); Dmax: 46.2±0.21 vs. 45.5±0.71 Gy (p=0.32). 
Conclusions: Incorporating 18-FDG-PET information in radiotherapy 
planning in patients with LD-SCLC changed the treatment plan in 
24% of patients compared to CT. Both increases and decreases of the 
GTV were observed, theoretically leading to the avoidance of respec-
tively geographical miss or a decrease of radiation exposure of normal 
tissues. Based on these ﬁndings, a phase II trial, evaluating PET-scan 
based selective nodal irradiation is ongoing in our department. 
PD6-2-1 Mesothelioman and Other Thoracic Malignancy, Mon, 16:00 - 17:30
Surgery of pulmonary metastases as a part of multimodality 
concept
Trakhtenberg, Alexander C.1 Parshin, Vladimir D.2 Pikin, Oleg V.1 
1 Hertzen Research Institute of Oncology, Dept. of Thoracic Surgery, 
Moscow, Russia 2 Russian Research Center of Surgery, Dept. of Tho-
racic Surgery, Moscow, Russia 
Introduction: The role of surgery in treatment of pulmonary metasta-
ses remains controversial. The treatment strategy depends on localiza-
tion and histology of the primary tumor, its differentiation degree and 
number of metastases. Selective group of patients can beneﬁt from 
curative pulmonary metastasectomy. The purpose of our study was to 
evaluate the role of aggressive pulmonary metastasectomy as a part of 
multimodality approach.
Material and Methods: 412 consecutive patients with pulmonary me-
tastases of different origin were operated on in our clinic. The histology 
of the primary tumor: cancer of different origin - 268, sarcoma - 117 
and melanoma - 27. Solitary metastases were diagnosed in 236, 2-3 
metastases - in 80 and multiple - in 87 patients. Selection criteria for 
surgery were: local control of the primary tumor, metastases located in 
the lungs, except colorectal cancer patients, resistance to conservative 
therapy.
Results: We performed 487 operations in 412 patients. Wedge resec-
tion was performed in 225 (54,7%), lobectomy - in 118 (28,6%), 
precision technique - in 36 (8,7%), segmentectomy - in 10 (2,4%), 
pneumonectomy - in 23 (5,6%) patients. Thoracotomy approach was 
used in 389, sternotomy - in 3, thoracoscopic resection - in 20 patients. 
Postoperative mortality was 1,2%. Conservative therapy was admin-
istered in all patients with poor prognosis. Overall survivals at 5 years 
were 34,9% of patients with solitary metastases, 21,7% of patients with 
2-3 nodules and 14,7% of patients with multiple pulmonary metastases. 
Better 5-year survival was achieved after surgery of gynecological 
cancer (45,5%), renal cancer (40,2%), head and neck cancer (38,4%) 
and colorectal cancer (33,4%). The results decreases in breast cancer 
(31,6%) and soft-tissue sarcomas (32,5%). No one survived more than 
5 years after surgery for metastatic melanoma. Overall 5-year survival 
was 52,4% of patients with DFI>36 months versus 22,6% with DFI<36 
months. Five-year survival with negative lymph nodes was 36,2%, 
while with positive lymph nodes - 0%.
Conclusion: Surgery as a component of multimodality treatment is jus-
tiﬁed, because it helps to achieve 5-year survival in that complex group 
of patients. Localization and histology of the primary tumor, number of 
metastases, DFI and status of intrathoracic lymph nodes are the most 
important prognostic factors.
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We performed genome-wide array-based comparative genomic hybrid-
ization (CGH) analysis of malignant pleural mesotheliomas (MPMs) to 
identify regions that display DNA copy number alterations. Seventeen 
primary tumors and 9 cell lines derived from 22 individuals were stud-
ied. Regions of genomic aberrations observed in > 20% of individuals 
were 1q, 5p, 7p, 8q24, and 20p of gains, and 1p36.33, 1p36.1, 1p21.3, 
3p21.3, 4q22, 4q34-qter, 6q25, 9p21.3, 10p, 13q33.2, 14q32.13, 18q, 
and 22q of losses. Two regions at 1p32.1 and 11q22 showed a high 
copy gain. The 1p32.1 region contained a protooncogene, JUN, and we 
further demonstrated overexpression of JUN with real-time polymerase 
chain reaction (PCR) analysis. Since JUN overexpression was observed 
in primary tumors but not in cell lines, our ﬁndings suggested that 
induction of JUN expression was involved in the development of MPM 
cells in vivo, which also might result in gene ampliﬁcation in a subset 
of MPMs. We also analyzed the 11q21-23 ampliﬁcation region and 
found that YAP1 was located in this region. Meanwhile, the most fre-
quent alteration was the 9p21.3 deletion, which includes the p16INK4a/ 
p14ARF locus. With PCR analysis, we determined the extent of the 
homozygous deletion regions of the p16INK4a/ p14ARF locus in MPM 
cell lines, which indicated that the deletion regions varied among cell 
lines. Our results provide new insights into the genetic background of 
MPM, and also give some clues to manifest a new molecular target 
therapy for MPM.
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Background: Serum markers have been tested in patients with 
malignant effusions for their ability to differentiate malignant pleural 
mesothelioma from other causes. So far no single tumor marker has 
been identiﬁed that differentiates mesothelioma from other causes. 
We therefore combined three different serum markers and report our 
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ﬁndings in a series of patients with different pleural malignancies and 
healthy controls. 
Methods: A retrospective analyses of 179 patients and 50 healthy 
controls was performed. Seventy-four patient had a conﬁrmed meso-
thelioma, and 110 patients had non small cell lung cancer of whom 56 
with an adenocarcinoma. Soluble Mesothelin Related Protein (SMRP), 
Cyfra 21.1 and Carcino Embrionic Antigen (CEA) were tested in serum 
at diagnosis of patients presenting with a suspected pleural malignancy. 
Results: Cyfra 21.1 was able to discriminate healthy from any thoracic 
malignancy with a sensitivity of 65% and speciﬁcity of 96%. The 
combination of CEA and SMRP was most accurate in differentiating 
mesothelioma from NSCLC (area under receiver operating characteris-
tics curve 0.94, 95% CI 0.90-0.97) and could thus identify 152 of 179 
(85%) cases. 
Conclusions: By using 2 serum markers (CEA and SMRP) we are able 
to discriminate mesothelioma from NSCLC with high sensitivity, while 
Cyfra 21.1 is useful in the discrimination of normal vs. malignancy. 
The relationship between groups and tumor markers by logistic regres-
sion models in univariate and multivariate analyses.
Tumor marker OR 95% CI p-value
Univariate 
Cyfra 21.1 (μgr/l) 1.00 0.99-1.02 0.515
SMRP (nmol/l) 1.64 1.26 <0.001
CEA (μgr/l) 0.45 0.33-0.61 <0.001
Multivariate 
SMRP (nmol/l) 2.02 1.27-3.21 0.003
CEA (μgr/l) 0.43 0.30-0.62 <0.001
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Background: Guidelines for the treatment of MPM do not advocate 
single modality treatment with either radiotherapy or surgery only. 
Since newer and more active chemotherapy became available for 
MPM, combined modality treatment (CMT) for earlier stages of MPM 
has been studied more intensively. We here report on the LLCG phase 
II prospective study of CMT for MPM patients, combining neoadjuvant 
chemotherapy, surgery and postoperative radiotherapy.
Methods: All consecutive MPM patients, candidates for CMT between 
March 2003 and December 2006, were included. Treatment consisted 
of induction chemotherapy with cisplatin 75 mg/m2 and pemetrexed 
500 mg/m2 on day 1 (3 cycles, q 3 wks), extrapleural pleuropneumo-
nectomy (EPP), and radiotherapy (mostly by intensity-modulated radio-
therapy; 54Gy/1.8Gy). Inclusion criteria were: age < 70 years, WHO 
Performance Status ≤1, medically ﬁt for pneumonectomy, staging of 
cT2N2M0 or less for epithelial subtypes, and cT2N1M0 or less for 
other histologic subtypes. All patients underwent thorough staging with 
PET-CT imaging, mediastinoscopy and laparoscopy. 
Results: A total of 29 MPM patients (men/women: 28/1; mean age 
± SD: 57.58 years ± 7.57) were included. Histologic subtypes were: 
epithelial (n=23); desmoplastic (n=1); sarcomatous (n=1); mixed (n=4). 
Five patients were found progressive after induction chemotherapy 
and went off protocol. Twenty patients underwent EPP (left/right EPP: 
7/13; R0/R1 resection 16/4), while 4 patients had an exploratory thora-
cotomy (irresectable MPM due to chest wall or oesophageal invasion). 
Resectability and complete resection rates were 20/24 (83.3%) and 
16/24 (66.6%), respectively. In one patient (male; 50 yrs; cT1bN0M0, 
left side MPM), a complete pathological response was observed. The 
in-hospital postoperative mortality was 2/24 (8.33%) and one re-tho-
racotomy for bleeding needed to be performed. Because 1 patient was 
estimated ineligible for irradiation (unique kidney) and another rapidly 
developed bone metastases, 16 patients ﬁnally started postoperative 
radiotherapy. One patient died just after ending radiotherapy (BOOP) 
and another didn’t complete radiotherapy (small bowel obstruction 
and respiratory infection). At the end, 15/29 patients completed the 
entire CMT protocol. Median survival (after MPM diagnosis) was 9.01 
months for all 29 patients who started CMT and 20.6 months for the 15 
patients who completed CMT, respectively.
Conclusions: This study demonstrates that CMT with neoadjuvant che-
motherapy, EPP and postoperative radiotherapy is feasible in dedicated 
centres and for well-elected MPM patients. The median survival for 
those patients who completed CMT is promising, but longer follow-up 
and validation of these results in future randomized controlled trials 
will be of interest. 
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Background: 18F-Fluorodeoxy glucose positron emission tomography 
(FDG- PET) is a promising tool for evaluating suspected malignancies 
throughout the body. Although there have been a few reports on FDG-
PET for imaging thymic epithelial tumors, its clinical usefulness and 
signiﬁcance are still unclear. The objective of this study was to analyze 
the degree of FDG-uptake in thymic epithelial tumors of different 
WHO histologic subtypes and stages.
Methods: We retrospectively reviewed FDG-PET ﬁndings in 35 
patients with thymic epithelial tumors (25 with thymomas and 10 with 
thymic carcinomas) treated between September 2002 and March 2007 
at Shizuoka Cancer Center. Twenty-three (66%) patients underwent 
surgical resection and the remaining 12 underwent only needle biopsy. 
The histologic subtype was determined according to the WHO clas-
siﬁcation in all 10 thymic carcinomas and 21 resected thymomas. The 
stage was determined according to Masaoka classiﬁcation in all 25 thy-
momas. FDG uptake in tumor using the maximum Standardized Uptake 
